269 related articles for article (PubMed ID: 28676213)
1. Urine circulating-tumor DNA (ctDNA) detection of acquired EGFR T790M mutation in non-small-cell lung cancer: An outcomes and total cost-of-care analysis.
Sands J; Li Q; Hornberger J
Lung Cancer; 2017 Aug; 110():19-25. PubMed ID: 28676213
[TBL] [Abstract][Full Text] [Related]
2. Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients.
Kuiper JL; Heideman DA; Thunnissen E; Paul MA; van Wijk AW; Postmus PE; Smit EF
Lung Cancer; 2014 Jul; 85(1):19-24. PubMed ID: 24768581
[TBL] [Abstract][Full Text] [Related]
3. Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer.
Yang X; Zhuo M; Ye X; Bai H; Wang Z; Sun Y; Zhao J; An T; Duan J; Wu M; Wang J
Oncotarget; 2016 Apr; 7(15):20810-24. PubMed ID: 26989078
[TBL] [Abstract][Full Text] [Related]
4. Longitudinal monitoring of ctDNA EGFR mutation burden from urine correlates with patient response to EGFR TKIs: A case series.
Tchekmedyian N; Mudad R; Blanco FF; Raymond VM; Garst J; Erlander MG; Haura E; Berz D
Lung Cancer; 2017 Jun; 108():22-28. PubMed ID: 28625639
[TBL] [Abstract][Full Text] [Related]
5. The role of T790M mutation in EGFR-TKI re-challenge for patients with EGFR-mutant advanced lung adenocarcinoma.
Zhang Q; Ke E; Niu F; Deng W; Chen Z; Xu C; Zhang X; Zhao N; Su J; Yang J; Yan H; Wu Y; Zhou Q
Oncotarget; 2017 Jan; 8(3):4994-5002. PubMed ID: 27999211
[TBL] [Abstract][Full Text] [Related]
6. Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance.
Zheng D; Ye X; Zhang MZ; Sun Y; Wang JY; Ni J; Zhang HP; Zhang L; Luo J; Zhang J; Tang L; Su B; Chen G; Zhu G; Gu Y; Xu JF
Sci Rep; 2016 Feb; 6():20913. PubMed ID: 26867973
[TBL] [Abstract][Full Text] [Related]
7. Detection of the T790M mutation of EGFR in plasma of advanced non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors (West Japan oncology group 8014LTR study).
Takahama T; Sakai K; Takeda M; Azuma K; Hida T; Hirabayashi M; Oguri T; Tanaka H; Ebi N; Sawa T; Bessho A; Tachihara M; Akamatsu H; Bandoh S; Himeji D; Ohira T; Shimokawa M; Nakanishi Y; Nakagawa K; Nishio K
Oncotarget; 2016 Sep; 7(36):58492-58499. PubMed ID: 27542267
[TBL] [Abstract][Full Text] [Related]
8. Quantification and dynamic monitoring of EGFR T790M in plasma cell-free DNA by digital PCR for prognosis of EGFR-TKI treatment in advanced NSCLC.
Wang Z; Chen R; Wang S; Zhong J; Wu M; Zhao J; Duan J; Zhuo M; An T; Wang Y; Bai H; Wang J
PLoS One; 2014; 9(11):e110780. PubMed ID: 25405807
[TBL] [Abstract][Full Text] [Related]
9. A Comparison of ddPCR and ARMS for detecting EGFR T790M status in ctDNA from advanced NSCLC patients with acquired EGFR-TKI resistance.
Wang W; Song Z; Zhang Y
Cancer Med; 2017 Jan; 6(1):154-162. PubMed ID: 28000387
[TBL] [Abstract][Full Text] [Related]
10. Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patients.
Ko R; Kenmotsu H; Serizawa M; Koh Y; Wakuda K; Ono A; Taira T; Naito T; Murakami H; Isaka M; Endo M; Nakajima T; Ohde Y; Yamamoto N; Takahashi K; Takahashi T
BMC Cancer; 2016 Nov; 16(1):864. PubMed ID: 27821131
[TBL] [Abstract][Full Text] [Related]
11. EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.
Otsuka K; Hata A; Takeshita J; Okuda C; Kaji R; Masago K; Fujita S; Katakami N
Cancer Chemother Pharmacol; 2015 Oct; 76(4):835-41. PubMed ID: 26349474
[TBL] [Abstract][Full Text] [Related]
12. T790M mutation is associated with better efficacy of treatment beyond progression with EGFR-TKI in advanced NSCLC patients.
Li W; Ren S; Li J; Li A; Fan L; Li X; Zhao C; He Y; Gao G; Chen X; Li S; Shi J; Zhou C; Fei K; Schmid-Bindert G
Lung Cancer; 2014 Jun; 84(3):295-300. PubMed ID: 24685306
[TBL] [Abstract][Full Text] [Related]
13. A Randomized Phase II Study Comparing Nivolumab With Carboplatin-Pemetrexed for Patients With EGFR Mutation-Positive Nonsquamous Non-Small-Cell Lung Cancer Who Acquire Resistance to Tyrosine Kinase Inhibitors Not Due to a Secondary T790M Mutation: Rationale and Protocol Design for the WJOG8515L Study.
Hayashi H; Chiba Y; Sakai K; Fujita T; Yoshioka H; Sakai D; Kitagawa C; Naito T; Takeda K; Okamoto I; Mitsudomi T; Kawakami Y; Nishio K; Nakamura S; Yamamoto N; Nakagawa K
Clin Lung Cancer; 2017 Nov; 18(6):719-723. PubMed ID: 28623122
[TBL] [Abstract][Full Text] [Related]
14. Association Between EGFR T790M Status and Progression Patterns During Initial EGFR-TKI Treatment in Patients Harboring EGFR Mutation.
Oya Y; Yoshida T; Kuroda H; Shimizu J; Horio Y; Sakao Y; Inaba Y; Hida T; Yatabe Y
Clin Lung Cancer; 2017 Nov; 18(6):698-705.e2. PubMed ID: 28596108
[TBL] [Abstract][Full Text] [Related]
15. EGFR T790M ctDNA testing platforms and their role as companion diagnostics: Correlation with clinical outcomes to EGFR-TKIs.
Liang Z; Cheng Y; Chen Y; Hu Y; Liu WP; Lu Y; Wang J; Wang Y; Wu G; Ying JM; Zhang HL; Zhang XC; Wu YL
Cancer Lett; 2017 Sep; 403():186-194. PubMed ID: 28642172
[TBL] [Abstract][Full Text] [Related]
16. Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer.
Villaflor V; Won B; Nagy R; Banks K; Lanman RB; Talasaz A; Salgia R
Oncotarget; 2016 Oct; 7(41):66880-66891. PubMed ID: 27602770
[TBL] [Abstract][Full Text] [Related]
17. Monitoring of treatment responses and clonal evolution of tumor cells by circulating tumor DNA of heterogeneous mutant EGFR genes in lung cancer.
Imamura F; Uchida J; Kukita Y; Kumagai T; Nishino K; Inoue T; Kimura M; Oba S; Kato K
Lung Cancer; 2016 Apr; 94():68-73. PubMed ID: 26973209
[TBL] [Abstract][Full Text] [Related]
18. Detection of epidermal growth factor receptor gene T790M mutation in cytology samples using the cobas
Satouchi M; Tanaka H; Yoshioka H; Shimokawaji T; Mizuno K; Takeda K; Yoshino I; Seto T; Kurata T; Tashiro N; Hagiwara K
Lung Cancer; 2017 Sep; 111():190-194. PubMed ID: 28838392
[TBL] [Abstract][Full Text] [Related]
19. Highly sensitive detection of EGFR T790M mutation using colony hybridization predicts favorable prognosis of patients with lung cancer harboring activating EGFR mutation.
Fujita Y; Suda K; Kimura H; Matsumoto K; Arao T; Nagai T; Saijo N; Yatabe Y; Mitsudomi T; Nishio K
J Thorac Oncol; 2012 Nov; 7(11):1640-4. PubMed ID: 22899358
[TBL] [Abstract][Full Text] [Related]
20. Urinary circulating DNA detection for dynamic tracking of EGFR mutations for NSCLC patients treated with EGFR-TKIs.
Chen S; Zhao J; Cui L; Liu Y
Clin Transl Oncol; 2017 Mar; 19(3):332-340. PubMed ID: 27468867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]